Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD receives approval for Phase 1 therapeutic study of NSCLC

Monday, October 9, 2023 1 min read
Key Takeaway: Radiopharm Theranostics (RADX) has received FDA approval to initiate a Phase 1 therapeutic study targeting B7H3 in non-small cell lung cancer (NSCLC). This study represents an important advancement in RAD's clinical research efforts. The approval is expected to facilitate further investigations into the efficacy of their therapeutic approach.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD has received FDA approval for a Phase 1 therapeutic study.
  • The study targets B7H3, which may have significant implications for NSCLC treatment.
  • This approval marks a crucial step in RAD's clinical development pipeline.

Full Press Release Details

• Announcements
• Price Sensitive
• October 9, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• August 27, 2024
• Announcements
• February 14, 2024
• Announcements
• August 18, 2023
• Announcements
• November 11, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What study has RAD received FDA approval for?

RAD has received FDA approval for a Phase 1 therapeutic study targeting B7H3 in NSCLC.

What is the significance of the B7H3 target?

Targeting B7H3 may have important implications for treating non-small cell lung cancer.

When was the FDA approval announced?

The FDA approval was announced on October 9, 2023.

What does this approval mean for RAD?

This approval marks a significant step in RAD's clinical development efforts.

Tags: RADX Viatris Investor Conferences Healthcare FDA approval NSCLC B7H3 therapeutic study
Last updated: Oct 9, 2023